HPGC Renmintongtai Pharmaceutical Corp (600829.SS) stock: key figures, P/E, revenue and dividend

Health Care · Health Care Distributors · China · ISIN CNE000000G05

Price
8.67 CNY
Market cap
5.03 bn CNY
P/E (2025)
37.56
P/S (2025)
0.48
Dividend yield
0.00 %
Net margin
1.29 %
Return on equity (ROE)
4.44 %
Return on assets (ROA)
1.87 %

HPGC Renmintongtai Pharmaceutical Corp financials

Fiscal year20242025
Revenue10.05 bn CNY10.38 bn CNY
Gross profit858.46 m CNY854.06 m CNY
Operating income288.90 m CNY290.45 m CNY
EBIT324.81 m CNY214.02 m CNY
Net income213.27 m CNY133.84 m CNY
Diluted EPS – continuing operations0.37 CNY0.23 CNY

Full history since 1990, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About HPGC Renmintongtai Pharmaceutical Corp

HPGC Renmintongtai Pharmaceutical Corporation engages in the wholesale and retail of pharmaceutical products in China and internationally. The company offers chemical drugs, traditional Chinese medicine, biological products, and medical supplies; medical instruments, traditional Chinese medicine decoction pieces, health foods, daily necessities, glassware, and chemical reagents, etc.; It serves its products through e-commerce platforms, direct sales, and a chain of direct stores and online B2C, O2O, etc. The company was founded in 1950 and is headquartered in Harbin, China. HPGC Renmintongtai Pharmaceutical Corporation is a subsidiary of Harbin Pharmaceutical Group Co., Ltd.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.